Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Cattrini

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of Medical Virology|July 14, 2021
SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral responseCinzia Borgogna, Marco De Andrea, Gloria Griffante, et al.
European Urology Oncology|August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysisCarlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Scientific Reports|October 18, 2023
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patientsCarlo Cattrini, Marcello Manfredi, Paola Barboro, et al.
Therapeutic Advances in Urology|July 26, 2023
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective studyChiara Tommasi, Giulia Scartabellati, Diana Giannarelli, et al.
Anti-Cancer Drugs|December 20, 2022
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinomaSebastiano Buti, Chiara Tommasi, Giulia Scartabellati, et al.
Clinical Genitourinary Cancer|December 11, 2024
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or EnzalutamideOrazio Caffo, Umberto Basso, Carlo Cattrini, et al.
Future Oncology (London, England)|April 28, 2025
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPCAntonello Veccia, Umberto Basso, Carlo Cattrini, et al.
Cancers|April 27, 2024
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint InhibitorsSara Mokbel, Giuilia Baciarello, Pernelle Lavaud, et al.
Therapeutic Advances in Urology|April 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patientsSebastiano Buti, Alessandro Olivari, Cristina Masini, et al.
Reviews in Cardiovascular Medicine|August 14, 2024
Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational StudyNicoletta Provinciali, Marco Piccininno, Giacomo Siri, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Medical Virology|July 14, 2021
SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral responseCinzia Borgogna, Marco De Andrea, Gloria Griffante, et al.
European Urology Oncology|August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysisCarlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Scientific Reports|October 18, 2023
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patientsCarlo Cattrini, Marcello Manfredi, Paola Barboro, et al.
Therapeutic Advances in Urology|July 26, 2023
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective studyChiara Tommasi, Giulia Scartabellati, Diana Giannarelli, et al.
Anti-Cancer Drugs|December 20, 2022
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinomaSebastiano Buti, Chiara Tommasi, Giulia Scartabellati, et al.
Clinical Genitourinary Cancer|December 11, 2024
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or EnzalutamideOrazio Caffo, Umberto Basso, Carlo Cattrini, et al.
Future Oncology (London, England)|April 28, 2025
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPCAntonello Veccia, Umberto Basso, Carlo Cattrini, et al.
Cancers|April 27, 2024
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint InhibitorsSara Mokbel, Giuilia Baciarello, Pernelle Lavaud, et al.
Therapeutic Advances in Urology|April 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patientsSebastiano Buti, Alessandro Olivari, Cristina Masini, et al.
Reviews in Cardiovascular Medicine|August 14, 2024
Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational StudyNicoletta Provinciali, Marco Piccininno, Giacomo Siri, et al.
Pageof 6